# Roche Holdings AG (RHHBY) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/RHHBY
## Company Profile
- Ticker: RHHBY
- Exchange: NASDAQ
- Sector: Biotechnology
- Location: United States
- Tags: Biologics, Pharmaceuticals, Diagnostics, APIs, Novel Therapies, Immunotherapy, Gene Therapy, Rare Disease Gene Therapy, Inherited Retinal Disease Gene Therapy, Small Molecule Drugs, Large Molecule Drugs, Antibody Drugs, Nucleic Acid Drugs, Oncology, Rare Disease, Ophthalmology
## Stock Data
- Close: 52.51 USD
- Market cap: Not available USD
- Last updated: 2026-10-05
## Business Overview
### Integrated Pharmaceuticals and Diagnostics Company
Roche is a global healthcare company that combines prescription medicines, diagnostic systems, and digital technologies within a single research and commercial organization. The group operates through Pharmaceuticals and Diagnostics divisions, with Genentech serving as its wholly owned U.S. biotechnology subsidiary and Chugai Pharmaceutical providing an additional research and development base in Japan.
### Broad Pharmaceuticals Franchise
Roche markets medicines across oncology, hematology, neurology, immunology, ophthalmology, and rare diseases. Major franchises include Ocrevus in multiple sclerosis, Hemlibra in hemophilia A, Vabysmo in retinal disease, Xolair in allergic disease, Phesgo in breast cancer, Tecentriq in oncology, and Evrysdi in spinal muscular atrophy.
### Oncology and Hematology Pipeline
The oncology portfolio spans antibodies, bispecifics, antibody-drug conjugates, targeted small molecules, and cancer immunotherapies. Key late-stage programs include giredestrant in estrogen receptor-positive breast cancer, divarasib in KRAS G12C-mutated lung cancer, Tecentriq in biomarker-defined early cancers, and combinations built around Lunsumio, Polivy, Columvi, Itovebi, and Gazyva/Gazyvaro.
### Neurology, Immunology and Ophthalmology
Roche is developing therapies for multiple sclerosis, Alzheimer's disease, Parkinson's disease, autoimmune neurological disorders, kidney-related immune diseases, and retinal conditions. Programs include fenebrutinib in relapsing and primary progressive multiple sclerosis, trontinemab in Alzheimer's disease, prasinezumab in Parkinson's disease, Enspryng across additional autoimmune indications, and Susvimo and Vabysmo in ophthalmology.
### Cardiometabolic and Obesity Programs
The cardiometabolic pipeline includes incretin, amylin, RNA-interference, and anti-inflammatory approaches. Enicepatide and petrelintide are being developed as individual and combination treatments for obesity, while other programs include zilebesiran in hypertension, pegozafermin in metabolic dysfunction-associated steatohepatitis, and selnoflast in cardiovascular and inflammatory disease.
### Diagnostics and Personalized Healthcare
Roche Diagnostics supplies core laboratory, molecular, near-patient, pathology, and companion-diagnostic systems. Its portfolio includes cobas laboratory platforms, Ventana tissue diagnostics, Elecsys immunoassays, the Axelios 1 next-generation sequencing platform, and digital algorithms designed to connect biomarker testing with treatment selection and disease monitoring.
## Why The Stock Is Moving

As of Oct 5, 2026, RHHBY closed up 0.50% at $52.51. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA decision on Tecentriq plus chemotherapy for stage III dMMR/MSI-H colon cancer by October 9, 2026.
- FDA decision on Enspryng for thyroid eye disease in October 2026.
- FDA decision on Gazyva/Gazyvaro for primary membranous nephropathy in November 2026.
- FDA PDUFA decision on giredestrant for adjuvant treatment of ER-positive early-stage breast cancer on November 30, 2026.
- FDA decision on giredestrant plus everolimus for ESR1-mutated, ER-positive advanced breast cancer in December 2026.
- FDA decision on Enspryng for MOGAD by January 10, 2027.

## Recent News
- 2026-10-01 06:00 EST — [Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions](https://biopharmsignal.com/news/RHHBY/roche-presents-new-data-at-euretina-highlighting-vabysmo-s-real-world-effectiven-85eb6858) — Source: Roche Holdings AG
- 2026-10-01 05:00 EST — [Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine](https://biopharmsignal.com/news/RHHBY/roche-s-giredestrant-combination-significantly-improved-progression-free-surviva-366d7079) — Source: Roche Holdings AG
- 2026-09-30 05:00 EST — [Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis](https://biopharmsignal.com/news/RHHBY/roche-s-fenebrutinib-is-the-first-btk-inhibitor-to-receive-u-s-fda-filing-accept-58ab83d7) — Source: Roche Holdings AG
- 2026-09-23 05:15 EST — [Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)](https://biopharmsignal.com/news/RHHBY/positive-interim-data-shows-roche-s-sefaxersen-significantly-reduces-proteinuria-78a01cdf) — Source: Roche Holdings AG
- 2026-09-23 05:00 EST — [Änderung im Verwaltungsrat von Roche](https://biopharmsignal.com/news/RHHBY/nderung-im-verwaltungsrat-von-roche-4b0cd6e2) — Source: Roche Holdings AG